Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multi-day fractionated administration schedule for paclitaxel

J Lokich1, N Anderson, M Bern

  • 1Cancer Center of Boston, MA, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 1, 1995
PubMed
Summary

Daily fractionated paclitaxel infusions are feasible in an outpatient setting, offering a potentially higher dose per cycle with manageable toxicity. This administration method does not require premedication and shows promise for dose escalation in select patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of WWγ Production and Search for Hγ Production in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

New Structures in the J/ψJ/ψ Mass Spectrum in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

Search for Scalar Leptoquarks Produced via τ-Lepton-Quark Scattering in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

Search for Inelastic Dark Matter in Events with Two Displaced Muons and Missing Transverse Momentum in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024
Same author

Evidence for the Higgs Boson Decay to a Z Boson and a Photon at the LHC.

Physical review letters·2024
Same author

Probing Small Bjorken-x Nuclear Gluonic Structure via Coherent J/ψ Photoproduction in Ultraperipheral Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2024

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Paclitaxel is a crucial chemotherapeutic agent.
  • Traditional administration involves longer infusion times.
  • Optimizing paclitaxel delivery is essential for improving patient outcomes and treatment efficiency.

Purpose of the Study:

  • To assess the feasibility of fractionating paclitaxel administration using daily one-hour infusions over three to five days.
  • To determine dose-escalation patterns and associated hematologic and non-hematologic toxicities.
  • To evaluate the safety and logistical aspects of outpatient paclitaxel fractionation.

Main Methods:

  • Forty patients received 87 courses of daily fractionated paclitaxel (3, 4, or 5 days per cycle) every 21 days.
  • Dose escalation ranged from 120 mg/m² to 250 mg/m² per cycle.

Related Experiment Videos

  • Six patients received concomitant daily cisplatin.

    • Main Results:

    • Cumulative doses per cycle reached up to 250 mg/m², with 25% of cycles at 200 mg/m² or higher.
    • Dose-limiting neutropenia occurred in 11.5% of cycles (grades 3 and 4).
    • No hypersensitivity reactions, hospitalizations, or need for cytokine support were observed.

    Conclusions:

    • Daily fractionated paclitaxel administration is logistically feasible in an ambulatory setting without requiring premedication.
    • Toxicity profiles are similar to single-day infusion schedules, with potential for higher dose intensity.
    • Optimal dosing for five-day schedules is 200-250 mg/m² per cycle; dose escalation beyond this may be possible in select patients. Concomitant cisplatin may increase neurotoxicity.